Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice

European Journal of Pharmacology

Volumn 650, Issue 2-3, 2011, Pages 550-555

  Barczyński, Bartłomiej ^a   Buszewicz, Grzegorz ^a   Łuszczki, Jarogniew J ^a,b   Bańka, Krzysztof ^a   Tutaj, Krzysztof ^a   Mróz, Tomasz ^a   Wielosz, Marian ^a   Ma̧dro, Roman ^a   Tutka, Piotr ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Antidepressant drug; Antiepileptic drug; Bupropion; Epilepsy; Seizure

Indexed keywords

AMFEBUTAMONE; FELBAMATE; LAMITRIN; LAMOTRIGINE; TOPIRAMATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN TISSUE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CONVULSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG POTENTIATION; ELECTRIC SHOCK; LOW DRUG DOSE; MALE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROTAROD TEST; SEIZURE; TREATMENT DURATION;

ANIMALS; ANTICONVULSANTS; BRAIN; BUPROPION; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ELECTROSHOCK; FRUCTOSE; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MOTOR ACTIVITY; PHENYLCARBAMATES; PROPYLENE GLYCOLS; PSYCHOMOTOR PERFORMANCE; ROTAROD PERFORMANCE TEST; SEIZURES; TRIAZINES;

EID: 78651083967     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.10.039     Document Type: Article

References (49)

1. M. Argyelan, Z. Szabo, B. Kanyo, A. Tanacs, Z. Kovacs, Z. Janka, and L. Pavics Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study J. Affect. Disord. 89 2005 115 123
2. M. Bialer, S.I. Johannessen, H.J. Kupferberg, R.H. Levy, P. Loiseau, and E. Perucca Progress report on new antiepileptic drugs: a summary of the Fourth Eilat conference (EILAT IV) Epilepsy Res. 34 1999 1 41
3. M. Bialer, D.R. Doose, B. Murthy, C. Curtin, S.S. Wang, R.E. Twyman, and S. Schwabe Pharmacokinetic interactions of topiramate Clin. Pharmacokinet. 43 2004 763 780
4. B.F. Bourgeois Pharmacokinetics and metabolism of topiramate Drugs Today (Barc.) 35 1999 43 48
5. L.S. Boylan, L.A. Flint, D.L. Labovitz, S.C. Jackson, K. Starner, and O. Devinsky Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy Neurology 62 2004 258 261 (Pubitemid 38167135)
6. B Receptors in Mammalian Function 1990 Wiley New York, NY 259 271
7. N.W. Dunham, and T.S. Miya A note on a simple apparatus for detecting neurological deficit in rats and mice J. Am. Pharm. Assoc. Am. Pharm. Assoc. (Baltim.) 46 1957 208 209
8. FDA's Approved Drug Products with Therapeutic Equivalence Evaluations Orange Book Annual Edition (28th Edition) Available via http://www.fda.gov/cder/ orange/obannual.pdf 2008 Last accessed Oct. 5th 2008
9. R.M. Ferris, and B.R. Cooper Mechanism of antidepressant activity of bupropion J. Clin. Psychiatry Monogr. 11 1993 2 14
10. R.N. Golden, C.L. De Vane, S.C. Laizure, M.V. Rudorfer, M.A. Sherer, and W.Z. Potter Bupropion in depression. II. The role of metabolites in clinical outcome Arch. Gen. Psychiatry 45 1988 145 149
11. M.D. Green, C.D. King, B. Mojarrabi, P.I. Mackenzie, and T.R. Tephly Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3 Drug Metab. Dispos. 26 1998 507 512
12. R. Guerrini, and L. Parmeggiani Topiramate and its clinical applications in epilepsy Expert Opin. Pharmacother. 7 2006 811 823
13. J.A. Johnston, C.G. Lineberry, J.A. Ascher, J. Davidson, M.A. Khayrallah, J.P. Feighner, and P. Stark A 102 center prospective study of seizure in association with bupropion J. Clin. Psychiatry 52 1991 450 456
14. T. Kanda, M. Kurokawa, S. Tamura, J. Nakamura, A. Ishii, Y. Kuwana, T. Serikawa, J. Yamada, K. Ishihara, and M. Sasa Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER) Life Sci. 59 1996 1607 1616
15. A.M. Kanner, and S. Palac Depression in epilepsy: a common but often unrecognized comorbid malady Epilepsy Behav. 1 2000 37 51
16. N.W. Kleckner, J.C. Głazewski, C.C. Chen, and T.D. Moscrip Subtype-selective antagonism of N-methyl-d-aspartate receptors by felbamate: insights into the mechanism of action J. Pharmacol. Exp. Ther. 289 1999 886 894
17. M. Kotlyar, L.H. Brauer, T.S. Tracy, D.K. Hatsukami, J. Harris, C.A. Bronars, and D.E. Adson Inhibition of CYP2D6 activity by bupropion J. Clin. Psychopharmacol. 25 2005 226 229
18. J.B. Kuzmiski, W. Barr, G.W. Zamponi, and B.A. MacVicar Topiramate inhibits the initiation of plateau potentials in CA1 neurons by depressing R-type calcium channels Epilepsia 46 2005 481 489
19. S.C. Lange, G.W. Fowler, and R.M. Julien Biphasic action of imipramine in laboratory models of epilepsy Proc. West. Pharmacol. Soc. 19 1976 198 203
20. S.M. Learned-Coughlin, M. Bergstrom, I. Savitcheva, J. Ascher, V.D. Schmith, and B. Langstrom In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography Biol. Psychiatry 54 2003 800 805
21. J.T. Litchfield Jr., and F. Wilcoxon A simplified method of evaluating dose-effect experiments J. Pharmacol. Exp. Ther. 96 1949 99 113
22. W. Löscher New visions in the pharmacology of anticonvulsion Eur. J. Pharmacol. 342 1998 1 13
23. J.J. Luszczki, and S.J. Czuczwar Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis Epilepsia 45 2004 895 907
24. R.L. Macdonald, and L.J. Greenfield Jr. Mechanisms of action of new antiepileptic drugs Curr. Opin. Neurol. 10 1997 121 128
25. S.A. Montgomery Antidepressants and seizures: emphasis on newer agents and clinical implications Int. J. Clin. Pract. 59 2005 1435 1440
26. F. Morazin, A. Lumbroso, P. Harry, M. Blaise, A. Turcant, P. Montravers, and R. Gauzit Cardiogenic shock and status epilepticus after massive bupropion overdose Clin. Toxicol. (Phila.) 45 2007 794 797
27. M. Nides Update on pharmacologic options for smoking cessation treatment Am. J. Med. 121 2008 S20 S31
28. P.N. Patsalos, and E. Perucca Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs Lancet Neurol. 2 2003 347 356 (Pubitemid 38352562)
29. E. Perucca A pharmacological and clinical review on topiramate, a new antiepileptic drug Pharmacol. Res. 35 1997 241 256
30. G.R. Pesola, and J. Avasarala Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department J. Emerg. Med. 22 2002 235 239
31. K.S. Rau, E. Birdsall, J.E. Hanson, K.L. Johnson-Davis, F.I. Carroll, D.G. Wilkins, J.W. Gibb, G.R. Hanson, and A.E. Fleckenstein Bupropion increases striatal vesicular monoamine transport Neuropharmacology 49 2005 820 830
32. D.J. Rissmiller, and T. Campo Extended-release bupropion induced grand mal seizures J. Am. Osteopath. Assoc. 107 2007 441 442
33. M.A. Rogawski, and R.J. Porter Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds Pharmacol. Rev. 42 1990 223 286
34. O. Salminen, K.L. Murphy, J.M. McIntosh, J. Drago, M.J. Marks, A.C. Collins, and S.R. Grady Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice Mol. Pharmacol. 65 2004 1526 1535
35. R. Seethalakshmi, and E.S. Krishnamoorthy Depression in epilepsy: phenomenology, diagnosis and management Epileptic Disord. 9 2007 1 10
36. G. Shepherd Adverse effects associated with extra doses of bupropion Pharmacotherapy 25 2005 1378 1382
37. P.H. Silverstone, R. Williams, L. McMahon, R. Fleming, and S. Fogarty Alcohol significantly lowers the seizure threshold in mice when co-administered with bupropion hydrochloride Ann. Gen. Psychiatry 7 2008 11 17
38. P.H. Silverstone, R. Williams, L. McMahon, R. Fleming, and S. Fogarty Convulsive liability of bupropion hydrochloride metabolites in Swiss albino mice Ann. Gen. Psychiatry 7 2008 19 26
39. S. Skradski, and H.S. White Topiramate blocks kainate-evoked cobalt influx into cultured neurons Epilepsia 41 Suppl. 1 2000 S45 S47
40. J.E. Slemmer, B.R. Martin, and M.I. Damaj Bupropion is a nicotinic antagonist J. Pharmacol. Exp. Ther. 295 2000 321 327
41. R.F. Suckow, T.M. Smith, A.S. Perumal, and T.B. Cooper Pharmacokinetics of bupropion and metabolites in plasma and brain of rats, mice, and guinea pigs Drug Metab. Dispos. 14 1986 692 697
42. E. Svensson, M.A. Wikstrom, R.H. Hill, and S. Grillner Endogenous and exogenous dopamine presynaptically inhibits glutamatergic reticulospinal transmission via an action of D2-receptors on N-type Ca2 + channels Eur. J. Neurosci. 17 2003 447 454
43. E.A. Swinyard, W.C. Brown, and L.S. Goodman Comparative assays of antiepileptic drugs in mice and rats J. Pharmacol. Exp. Ther. 106 1952 319 330
44. P. Tutka, B. Barczyński, and M. Wielosz Convulsant and anticonvulsant effects of bupropion in mice Eur. J. Pharmacol. 499 2004 117 120
45. P. Tutka, T. Mróz, K. Klucha, M. Piekarczyk, and M. Wielosz Bupropion-induced convulsions: preclinical evaluation of antiepileptic drugs Epilepsy Res. 64 2005 13 22
46. P. Unverir, R. Atilla, O. Karcioglu, H. Topacoglu, Y. Demiral, and Y. Tuncok A retrospective analysis of antidepressant poisonings in the emergency department: 11-year experience Hum. Exp. Toxicol. 25 2006 605 612
47. R.M. Welch, A.A. Lai, and D.H. Schroeder Pharmacological significance of the species differences in bupropion metabolism Xenobiotica 17 1987 287 298
48. H.S. White, S.D. Brown, J.H. Woodhead, G.A. Skeen, and H.H. Wolf Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism Epilepsia 41 Suppl. 1 2000 S17 S20
49. X. Zhang, A.A. Velumian, O.T. Jones, and P.L. Carlen Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate Epilepsia 41 Suppl. 1 2000 S52 S60